Navigation Links
Cowen Healthcare Royalty Partners Raises $1 Billion
Date:1/5/2012

STAMFORD, Conn., Jan. 5, 2012 /PRNewswire/ -- Cowen Healthcare Royalty Partners (Cowen Royalty), a global healthcare investment firm, today announced the closing of Cowen Healthcare Royalty Partners II, L.P. (CHRP II).  With approximately $1 billion in new capital commitments, Cowen Royalty will sustain its broad strategy of investing in traditional passive royalties, Synthetic royalties® and structured financings. Cowen Royalty exceeded the initial target for CHRP II by more than 75 percent.

"With a large amount of fresh capital and a healthy pipeline of financing opportunities and royalty asset sales, we believe we are well positioned to capitalize on this growing multi-billion dollar market opportunity," commented Clarke B. Futch, Founding Managing Director at Cowen Royalty.

Similar to its first fund, Cowen Royalty will target investments between $20MM-$100MM in the U.S., Europe and Asia.  The two main categories for capital investments include commercial stage biopharmaceutical and medical device companies in need of growth capital, and universities/inventors looking to monetize product interests.

"Increased demand for alternatives to traditional debt or equity by both companies and royalty owners will continue to drive this finance category going forward," further commented Cowen Royalty Founding Managing Director Todd C. Davis.

Since raising CHRP I in 2008, Cowen Royalty has made a total of 20 investments in 17 products including Lexiva® (GlaxoSmithKline), Cetrotide® (Merck Serono), Myozyme® (Genzyme, a Sanofi Company), Qutenza® (Astellas Pharma), Oracea® (Galderma) and KAMRA® inlay (AcuFocus). During the second half of 2011, Cowen Royalty closed eight (8) deals including product focused investments with Dyax Corp (DYAX), Stereotaxis, Inc. (STXS) and Zogenix (ZGNX), and royalty monetizations with several universities.  The Firm has continued to strengthen its team, adding experienced investment, financial, legal and operations professionals under the leadership of co-founders Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Futch.

In addition to existing Cowen Royalty limited partners, CHRP II LP's consist of a world-class list of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments.

Credit Suisse Securities (USA) LLC acted as exclusive financial advisor/placement agent and Goodwin Procter LLP as legal counsel.

About Cowen Healthcare Royalty Partners

Founded in 2007, Cowen Healthcare Royalty Partners is a global healthcare investment firm with over $1.5 billion of capital under management. The Firm specializes in structured financing solutions for the life sciences industry. For more information, visit www.cowenroyalty.com.

Media Contact:         

Kellie Walsh
914-315-6072
kwalsh@kwmcommunications.com

 


'/>"/>
SOURCE Cowen Healthcare Royalty Partners
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
3. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
4. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
5. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
6. Life Technologies to Present at the Cowen and Company 31st Annual Health Care Conference
7. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
8. Savient to Present at the Cowen and Company 30th Annual Health Care Conference
9. Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board
10. RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference
11. Amgen to Present at the Cowen and Company Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... , ... October 09, 2017 , ... The award-winning American ... broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , ... faced with the challenge of how to continue to feed a growing nation. At ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
(Date:10/6/2017)... ... 06, 2017 , ... On Tuesday, October 24th, ABC² (Accelerate ... first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. ... open to the public, but registration is required. , WHAT: ABC² Brain ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):